BMY Relative Valuation
BMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BMY is overvalued; if below, it's undervalued.
Historical Valuation
Bristol-Myers Squibb Co (BMY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.08 is considered Undervalued compared with the five-year average of 2.87. The fair price of Bristol-Myers Squibb Co (BMY) is between 62.33 to 80.42 according to relative valuation methord. Compared to the current price of 48.18 USD , Bristol-Myers Squibb Co is Undervalued By 22.70%.
Relative Value
Fair Zone
62.33-80.42
Current Price：48.18
22.70%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
5.64
P/B
Median3y
5.03
Median5y
4.43
13.84
FCF Yield
Median3y
10.47
Median5y
10.00
Competitors Valuation Multiple
The average P/S ratio for BMY's competitors is 3.43, providing a benchmark for relative valuation. Bristol-Myers Squibb Co Corp (BMY) exhibits a P/S ratio of 2.08, which is -39.30% above the industry average. Given its robust revenue growth of -5.60%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Bristol-Myers Squibb Co (BMY) currently overvalued or undervalued?
What is Bristol-Myers Squibb Co (BMY) fair value?
How does BMY's valuation metrics compare to the industry average?
What is the current P/B ratio for Bristol-Myers Squibb Co (BMY) as of May 13 2025?
What is the current FCF Yield for Bristol-Myers Squibb Co (BMY) as of May 13 2025?
What is the current Forward P/E ratio for Bristol-Myers Squibb Co (BMY) as of May 13 2025?